XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Adjusted PAT declined 18.8% YoY
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Subscribe To Our Newsletter & Stay Updated
